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ABSTRACT
Bone tissue engineering could provide an alternative to conventional treatments for fracture
nonunion, spinal fusion, joint replacement, and pathological loss of bone. However, this approach
will require a biocompatible matrix to allow progenitor cell delivery and support tissue invasion.
The construct must also support physiological loads as it degrades to allow the regenerated tissue
to bear an increasing load. To meet these complex requirements, we have employed topology-opti-
mized design and solid free-form fabrication to manufacture biodegradable poly(propylene fu-
marate)/-tricalcium phosphate composites. These scaffolds were seeded with primary human fi-
broblasts transduced with an adenovirus expressing bone morphogenetic protein-7 and implanted
subcutaneously in mice. Specimens were evaluated by microcomputed tomography, compressive
testing, and histological staining. New bone was localized on the scaffold surface and closely fol-
lowed its designed contours. Furthermore, the total stiffness of the constructs was retained for up
to 12 weeks after implantation, as scaffold degradation and tissue invasion took place.
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INTRODUCTION
SEVERAL CLINICAL SITUATIONS, including fracturenonunion, spinal fusion, joint replacement, and patho-
logical loss of bone, could all be improved by the abil-
ity to tissue engineer bone.1–6 It has been well established
that tissue engineering requires an appropriate matrix that
is biodegradable and biocompatible, allows for delivery
of appropriate progenitor cells or biofactors, and supports
the invasion of the desired tissue and blood supply.7–9
For bone tissue engineering, however, the need to main-
tain adequate mechanical properties to perform properly
in a load-bearing site adds another level of complex-
ity.10–12 This performance requires compressive strength
great enough to bear the load, but low enough to not
greatly exceed that of the adjacent bone tissue, as this
may trigger stress shielding and subsequent bone resorp-
tion. Furthermore, as the scaffold degrades and its me-
chanical properties decline, the physiological forces must
be transferred to the regenerated tissue.10 In this dynamic
situation, designing scaffolds that possess appropriate
mechanical properties and allow tissue ingrowth can be
greatly improved by computational scaffold optimization
and fabrication.13
Much of bone tissue engineering and, indeed, tissue
engineering in general, currently employs scaffolds made
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by techniques such as gas foaming and salt leaching.14–21
These methods create highly porous scaffolds that have
been used to engineer a variety of tissues.22–25 However,
the internal features and the interconnectivity of created
pores/conduits cannot be designed a priori. In addition,
these methods do not allow for the creation of complex
external geometries that could match anatomical defect
sites; branching structures; or complex, oriented internal
pore geometry. The lack of well-defined internal topol-
ogy may be a barrier to proper tissue penetration. We
have developed computational scaffold optimization
techniques the can overcome these limitations.26,27 They
allow for design of a scaffold that simultaneously pos-
sesses load-bearing capacity and interconnected designed
porosity, which allows biofactor delivery and mechani-
cal stimulation of regenerated tissue. Topology opti-
mization is a design technique that provides optimal dis-
tribution of material under applied force to satisfy the
objective of maximal stiffness with desired porosity, un-
der constraints of the design criteria.26–29 This approach
addresses the conflicting design issues of having suffi-
cient load-bearing capability while at the same time hav-
ing enough interconnected porosity to deliver biofactors
such as cells, genes, and proteins and to impart sufficient
mechanical strain to maintain developing tissue.
These topology-optimized scaffolds can then be 
manufactured by indirect solid free-form fabrication
(SFF).13,30,31 Indirect SFF employs the fabricated struc-
tures as molds and allows the creation of scaffolds from
a large number of materials.31–33 This technique allows
the creation of scaffolds with designed external and in-
ternal geometry cast from a biodegradable composite of
poly(propylene fumarate) incorporating -tricalcium
phosphate (PPF/-TCP). PPF/-TCP is a promising new
material for the tissue engineering of bone for several
reasons. It has been postulated that the mechanical prop-
erties of this composite increase during the early stage of
degradation by means of a reinforcement mechanism,
most likely due to continued cross-linking, and also by
forming complexes of polymeric carboxylic acid groups
with calcium ions.34–36 This continued stiffness increase
before degradation, along with the lack of acidic degra-
dation products from commonly used poly(-hydroxy es-
ters), may make PPF/-TCP more suitable for load-bear-
ing orthopedic applications. It has also been shown that
PPF/-TCP substrates provide an osteoconductive sur-
face that facilitates the proliferation and differentiation
of marrow stromal osteoblasts.37
To effectively engineer bone, scaffolds must be seeded
with appropriate progenitor cells or growth factors. Gene
therapy may provide an alternative to these options, with-
out the need for large amounts of expensive recombinant
proteins or progenitor cells that may be difficult to har-
vest and expand. It has been previously shown that eas-
ily harvested and expanded cells may be transduced to
express factors that initiate bone formation.38–41 This so-
called ex vivo gene therapy approach has been shown to
trigger ectopic bone formation and healing of segmental
and cranial defects in animal models.38,40 Such trans-
duced cells have already shown promise in producing
bone on porous designed scaffolds.42
In this study, we combined ex vivo gene therapy with
designed, solid free-form fabricated scaffolds to regen-
erate a functional bone construct. Topology-optimized
composite scaffolds made from PPF/-TCP were seeded
with human fibroblasts transduced to express bone mor-
phogenetic protein-7 (BMP-7). After ectopic implanta-
tion in a murine model, the scaffolds were evaluated me-
chanically and histologically, and by microcomputed
tomography. These data allowed us to evaluate the quan-
tity and quality of bone produced by this combined ap-
proach. In addition, we have evaluated the dynamic me-
chanical properties of the implants as bone invaded the
scaffold and the PPF/-TCP degraded. The results dem-
onstrated that the integration of computational optimiza-
tion, indirect SFF using a biodegradable PPF/-TCP
composite, and ex vivo gene therapy produced a func-
tional osteogenic construct for bone tissue engineering.
MATERIALS AND METHODS
Design and manufacture of scaffolds
A hierarchical integrated topology optimization tech-
nique accounting for degradation was used to design the
scaffolds as previously described.26 Briefly, the opti-
mization method creates a density distribution map
within the design domain that accommodates the subcu-
taneous scale with dimensions of 6 mm in diameter and
4 mm in height, for selected time points during degrada-
tion. These different density distributions are then su-
perposed, using both time-lasting and time-degrading
modulus weighting factors. This forms the basis of the
macroscopic or first hierarchical scale-optimized topol-
ogy to provide the general density and location of mate-
rial within the design domain. The microscopic or sec-
ond-scale topology optimization approach gives the
specific microstructure design that achieves a desired
compliance while matching the predicted volume frac-
tion of the macroscopic or first-level topology optimiza-
tion.26,27 The final scaffold design was 50% porous with
pore sizes ranging from 300 to 1000 m. The entire scaf-
fold design can then be generated by assigning the de-
signed microstructures to the corresponding global den-
sity layout (Fig. 1).
Fifty-six wax molds of the designed scaffolds were
fabricated on a ModelMaker II three-dimensional rapid
prototyping system (Solidscape, Merrimack, NH). A
paste was generated by dissolving 1.0 g of synthesized
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PPF (MW, 1500 Da; polydispersity index, 2.2)35,43 and
0.02 g of the initiator benzoyl peroxide (Sigma, St. Louis,
MO) in 1.0 mL of the monomer N-vinyl pyrrolidinone
(Sigma). After complete dissolution, 0.6 g of -TCP
(Plasma Biotal, North Derbyshire, UK) was added. Fi-
nally, 1 L of the accelerator N,N-dimethyl-p-toluidene
(Sigma) was added just before casting to induce cross-
linking. This PPF/-TCP paste was forced into the molds.
After casting, molds were held in a nitrogen chamber at
room temperature for 24 h. The samples were then treated
with acetone (Fisher Scientific, Fair Lawn, NJ) to dis-
solve the molds. The scaffolds were subsequently rinsed
in distilled water for 24 h and then sterilized in 70% eth-
anol (Fisher Scientific) for 24 h.
Seeding and implantation
Primary human gingival fibroblasts were prepared
from explants of human surgical waste in compliance
with the University of Michigan (Ann Arbor, MI) Insti-
tutional Review Board. Primary explants of gingival fi-
broblasts were expanded in -minimum essential
medium (-MEM) containing 10% fetal bovine plasma
and 1% penicillin–streptomycin (GIBCO; Invitrogen,
Frederick, MD).44 Passage 4 fibroblasts were infected
with AdCMV-BMP-7, a first-generation recombinant ad-
enovirus construct expressing the murine BMP-7 gene
under the control of the cytomegalovirus (CMV) pro-
moter. The virus was created by Cre–lox recombination
as previously described.45 Cells thus infected have been
previously shown to express BMP-7 in vitro, trigger ec-
topic bone formation, and heal critically sized murine cra-
nial defects.38,41,45 Infections were performed overnight
with 200 plaque-forming units per cell. Cells were seeded
in a 2-mg/mL collagen gel made from acid-solubilized
rat tail collagen (BD Biosciences Discovery Labware,
Bedford, MA) diluted in phosphate-buffered saline
(GIBCO), adjusted to pH 7.0 with 1 N NaOH (Sigma).
The scaffolds were placed in tight-fitting molds and 30
L of the collagen containing 2 million cells was pipet-
ted into each scaffold. Scaffolds were then placed in a
37°C incubator for 20 min to allow gelation of the col-
lagen.
Twenty-four scaffolds seeded with virally trans-
duced fibroblasts, 8 scaffolds seeded with untransduced
fibroblasts, and 24 scaffolds without cells were im-
planted subcutaneously into 5- to 8-week-old immuno-
compromised mice (N:NIH-bg-nu-xid; Charles River,
Wilmington, MA). Animals were anesthetized with in-
traperitoneal injections of ketamine–xylazine (50 and
5 g/g, respectively) in saline. Subcutaneous pockets
were created by blunt dissection and four scaffolds
were inserted into each mouse. Surgical sites were
closed with wound clips.
FIG. 1. Topology optimization was used to design the scaffold (A) and it internal architecture (B). This design was faithfully
produced in the fabricated PPF/-TCP scaffold [top (C) and bottom (D)].
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Evaluation of scaffolds and generated tissue
Mice were killed after 2, 4, 8, or 12 weeks. The har-
vested implants were fixed with Z-Fix (Anatech, Battle
Creek, MI) and stored in 70% ethanol for microcomputed
tomography (CT) analysis. Specimens were scanned by
CT in water, using an MS-130 high-resolution MicroCT
scanner (GE Medical Systems, London, ON, Canada) at
15-m voxel resolution and 75 kV. Three-dimensional
isosurface renderings were made with MicroView ver-
sion 1.1.1 (GE Medical Systems). Image threshold lev-
els were automatically calculated by applying the au-
tothreshold algorithm from the histogram presented in
MicroView, and volume fractions of the scanned scaf-
folds were thus generated. Because of the difficulty in
extracting new-forming bone tissue from the new con-
structs, resulting from the identical gray-scale density of
calcified bone tissue with -tricalcium phosphate in the
scaffold composite, total solid volumes of empty scaf-
folds and tissue caffold constructs were calculated by
multiplying the volume of the defined region of interest
by individual volume fractions. Last, regenerated bone
volumes were calculated by subtracting the average vol-
umes of empty scaffolds from those of tissue caffold con-
structs.
After CT scanning, histological evaluation was con-
ducted on three of the cell-seeded scaffolds and one of
the empty scaffolds from each implantation time. These
scaffolds were demineralized with RDO (Apex Engi-
neering Products, Aurora, IL).31 The scaffolds were then
FIG. 2. CT data were used to create three-dimensional surface renderings. A photograph of the scaffold (top left) and a scan
of a scaffold that was not implanted (week 0) are provided for comparison. The renderings show an increase in bone volume at
2 weeks, followed by a slight decrease at 4 weeks. Full coverage of the scaffold by bone was observed at 8 weeks. Somewhat
less bone appeared to be covering the scaffold after 12 weeks than after 8 weeks.
FIG. 3. Cross-sections of the CT data reveal increased bone apposition 2, 4, 8, and 12 weeks postimplantation. As implanta-
tion time increased, bone was more highly localized, closely following the scaffold contours (arrows).
FUNCTIONAL BONE ON OPTIMIZED SCAFFOLDS 1593
embedded in paraffin, sectioned at 7 m, and stained with
hematoxylin and eosin (H&E).
A subset of scaffolds was not demineralized and was
subjected to mechanical testing. A 0.5-lb preload was ap-
plied followed by a compressive test to failure at a cross-
head speed of 1 mm/min (ASTM D695-02a; Standard
Test Method for Compressive Properties of Rigid Plas-
tics), using an MTS Alliance RT30 electromechanical test
frame (MTS Systems, Eden Prairie, MN). The compres-
sion test was continued until failure, when a drop took
place in the real-time compressive load–displacement
curve. Load versus deflection was continuously moni-
tored and recorded, and values of peak load and effec-
tive compressive moduli, defined as the slope of the lin-
ear region at the stress–strain curve, were then calculated
by the system.
RESULTS
The fabrication of PPF/-TCP scaffolds showed that
the mold-casting process successfully reproduced fea-
tures from the original designs (Fig. 1). Scaffolds were
seeded with BMP-7-transduced or untreated human fi-
broblasts or left empty. After subcutaneous implantation
in mice for 2, 4, 8, or 12 weeks, the scaffolds were re-
moved and fixed. Three-dimensional surface rendering
of reconstructed scanned CT images showed that no
bone was observed on empty scaffolds or on scaffolds
seeded with untransduced fibroblasts. However, in-
creased accumulation of bone over time was noted on
those scaffolds seeded with transduced fibroblasts (Fig.
2). After 2 weeks in vivo, new bone had formed and cov-
ered the scaffold along the designed contours. At 4 weeks,
the covering area decreased. Interestingly, a circumfer-
ential pattern of conduits started to form on the forming
bone shell. After 8 weeks, the circumferential pattern had
progressed and covering of cortical bone was observed
around a large portion of the scaffold. After 12 weeks,
however, a loss of bone was apparent on the three-di-
mensional image of the construct. The layer of cortical
bone that existed at earlier implantation times became
less dense, with disconnected bone fragments. Cross-sec-
tional images of the CT data showed bone infiltration
in the circumferential channels at 2 weeks, and infiltra-
tion into the center well at 4 weeks (Fig. 3). The appo-
sition of new bone increased progressively along the de-
signed contours as implantation time lengthened.
Interestingly, the bone localized on the scaffold contours
became thicker and appeared brighter in the CT images.
The data from the CT scans were used to calculate
bone volume and showed little change in bone volume
(Table 1). Changes in bone formation after increased
implantation times were reflected largely in the geom-
etry of the bone.
After CT scanning of all implants, three cell-seeded
scaffolds and one empty scaffold from each implantation
time were decalcified, embedded in paraffin, sectioned,
and stained with H&E (Fig. 4). Histological sections cor-
roborated the CT data shown in Fig. 3. Specifically,
H&E staining demonstrated, at low magnification, in-
creased formation of bone over 2, 4, and 8 weeks, and a
slight loss of bone after 12 weeks. These sections also
revealed additional morphological features of the newly
formed tissue. After a 2-week implantation, a thin exte-
rior cortex of bone surrounded a large quantity of fibrous
tissue. Bone at this point remained fairly unorganized. At
the 4-week point, a larger quantity of bone was observed,
somewhat more organized, and marrow was present.
Compared with the 2-week specimens, the 4-week spec-
imen clearly formed bone and more deeply penetrated the
scaffold. The progression of increased organization, bone
volume, and bone penetration continued at week 8. Fi-
nally, after 12 weeks the bone remained organized, but
bone volume diminished slightly. However, the cortical
bone appeared thicker and located increasingly around
the interior pores. Scaffolds were sliced along the longi-
tudinal axis of the scaffold at 8 weeks to determine
whether the bright rims on the CT scan around the de-
signed contour were due to calcium binding on the com-
posite or to actual bone forming on the scaffold surface.
The histology revealed that these bright rims were indeed
TABLE 1. MICROCOMPUTED TOMOGRAPHY USED TO CALCULATE BONE VOLUMEa
Bone volume (mm3)
Week 0 Week 2 Week 4 Week 8 Week 12
Bone–scaffold construct 45.80  1.51b 55.28  5.23 53.88  2.91 55.33  4.12 52.66  3.40
Effective bonec 11.21  5.23 8.08  2.91 9.53  4.12 6.86  3.40
aBone volume changed only slightly with time, and was not found to be significant at the 95% confidence interval.
bThe average volume of empty scaffolds.
cFor each specimen, effective bone volume is defined as (volume of bone–scaffold construct)  (average volume of empty 
scaffolds).
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compact bone tissue deposited on the surface of osteo-
conductive PPF/-TCP composite. As in the CT scans,
only fibrous tissue was observed on the scaffolds seeded
with untreated fibroblasts. These scaffolds were not in-
cluded in any the subsequent mechanical testing.
For each experimental group, all those scaffolds not
histologically evaluated (that is, three scaffolds seeded
with cells and five empty scaffolds) were subjected to
mechanical testing to determine compressive modulus
and peak load. Continuously decreasing compressive
modulus was observed with empty scaffolds, demon-
strating in vivo degradation through the entire implan-
tation time. However, the total compressive modulus
of bone caffold constructs remained at a plateau level
of 60 MPa, indicating that bone growing through the
scaffold reinforced the construct and compensated for
the degrading scaffold modulus (Fig. 5). The effective
compressive modulus of the regenerated bone was cal-
culated by directly subtracting the average compressive
modulus of empty scaffolds from that of the construct
at each time point, resulting in 7.89  0.97 MPa,
18.02  2.12 MPa (p  0.05), 33.80  16.46 MPa,
and 24.04  0.30 MPa (p  0.05) at 2, 4, 8, and 12
weeks, respectively. The ultimate load-carrying capac-
ity was defined by the peak load that failed the speci-
men under uniaxial compression. The peak loads were
113.13  8.33, 86.08  20.07, 103.09  18.89, and
80.88  21.17 N at 2, 4, 8, and 12 weeks, respectively.
The effective peak loads on regenerated bone were then
calculated by subtracting the average peak loads of
empty scaffolds (56.31, 54.50, 30.11, and 42.03 N)
from that of the construct at each time point. There-
fore, the effective peak loads on bone regenerated at
each predetermined time point were 56.82  8.33,
43.18  0.58, 72.99  18.89, and 50.57  8.57 N at 2,
4, 8, and 12 weeks, respectively. At the 95% confi-
FIG. 4. Middle and right: Hematoxylin and eosin staining confirmed the presence of bone (b), in agreement with that shown
in the matched CT reconstructions (left). Middle: Low-magnification images (2) show trabecular bone (b), a layer of cortical
bone surrounding the scaffold (c), and the residual scaffold material (s). A “front” of bone (*) was observed to progress deeper
into the scaffold interior with increasing implantation times. Right: Higher magnifications (40) of the red-outlined areas reveal
normal morphological formation of bone with marrow.
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dence interval, no significance was found for the dif-
ference between effective peak loads over time.
DISCUSSION
Effective tissue engineering of a load-bearing tissue
such as bone requires a scaffold with appropriate me-
chanical properties that endure until the regenerated bone
can carry load. In an ideal system, cells would differen-
tiate into the desired tissue within a porous scaffold and,
as growth continues, the degrading scaffold would bear
less of the mechanical load as the nascent bone bore an
increasing amount. Here we have demonstrated a system
that has the potential to achieve these goals. Scaffolds
were computationally designed to be optimal for bearing
load and allowing tissue ingrowth and then manufactured
from a degradable polymer, PPF, reinforced with a ce-
ramic, -TCP. When these scaffolds were seeded with
fibroblasts transduced to express BMP-7 and implanted
subcutaneously, organized bone with marrow formed in
and around the scaffold. Over increasing implantation
times, the amount of bone and its compressive modulus
both increased as the scaffold degraded. Key to achiev-
ing these results was combined the advantages of topol-
ogy optimization, free-form fabrication of a ceramic-re-
inforced degradable polymer, and ex vivo gene therapy.
Topology optimization allows great flexibility in al-
tering hierarchical pores for various purposes, such as to
create wide-open channels in the macrostructure to allow
initial mass exchange and small pores in the microstruc-
tural architecture to maintain required porosity for blood
vessel invasion but still retain mechanical integrity. Un-
like traditional techniques, which create porous scaffolds
by the use of porogens such as sodium chloride, the size
and distribution of the pores of topology-optimized scaf-
folds are the outcome of computational results, rather
than predetermined by a porogen. Reconstructions from
our CT data confirm that the design does perform as
expected, in that we observed a bone formation ront that
moved with increasing implantation times (Fig. 3). The
front moved from the top of the center well until it coa-
lesced with the infiltration of bone tissue from small pores
to complete the full bone ingrowth. It is possible that the
observed concentric-like patterns allowed the invasion of
blood vessels (Fig. 2). It is also possible, however, that
these channels were created by bone resorption triggered
by lack of mechanical stimulation in the subcutaneous
site. Whether these patterns will be affected by the de-
sign or be dominated by the loading milieu is not yet
known.
The second key component of the approach described
in this article was the use of the composite PPF/-TCP
material. PPF/-TCP has been shown to be highly os-
teoconductive37 and the work presented here confirms
this in that bone formation was highly localized along the
designed contours when scaffolds were seeded with
transduced fibroblasts (Figs. 2 and 3). However, because
no bone was observed on scaffolds seeded with untreated
fibroblasts, it is clear that the osteoinductivity of this sys-
tem derives from the presence of BMP-7 secreted by the
transduced fibroblasts. Manipulating tissue aterial affin-
FIG. 5. Over increasing implantation times, the compressive modulus of the scaffold declined and the modulus of the tissue
increased. These simultaneous phenomena resulted in a modulus for the entire construct that was nearly constant.
ity through the addition of particles, such as the ceramic
used here, helped direct bone ingrowth into pores as small
as 400 m in diameter. The combination of topology-op-
timized designs with osteoconductive biodegradable
polymer composite can fulfill the goal of load bearing at
the initial stage as a suitable tissue-engineering strategy.
Finally, the use of ex vivo gene therapy enabled the
production of large amounts of biologically and me-
chanically functional tissue without the use of specific
progenitor cells. Further, the use of transduced fibroblasts
allowed osteogenesis to commence quickly and fill the
designed void space with organized bone tissue and mar-
row (Fig. 3). Therapeutically, autologous fibroblasts rep-
resent an easily biopsied source of immunocompatible
cells that can be manipulated in vitro to express the de-
sired transgene. When combined with an optimally de-
signed scaffold of appropriate material composition, the
transduced primary cells can combine with host cells to
generate large amounts of functional tissue.38 Adenovi-
ral vectors, such as those utilized in this study, do pre-
sent certain safety concerns, particularly immmuno-
genicity of the virus.46,47 However, in the ex vivo
approach we employed, cells transduced in vitro, rather
than viral particles, are implanted, which may minimize
the immune response. Further, the technique of seeding
optimized scaffolds with transduced cells may be equally
effective when used in conjunction with the newer, safer
gene therapy vectors currently being developed.48,49
This combined approach has brought us a step closer
to realizing the theoretical goal of using scaffolds in tis-
sue engineering: a degradable biomaterial that allows
functional tissue regeneration while retaining its overall
mechanical properties as the scaffold degrades with re-
duced support resistance. In this idealized system, the
scaffold provides initial function in the tissue defect and,
as the scaffold material degrades, nascent bone increas-
ingly compensates for the loss of mechanical function,
allowing maintenance of a constant stiffness within the
range of normal tissue.10 Although our results do not fully
duplicate this idealized scenario, they do show that the
combined bone–scaffold construct had nearly constant
mechanical properties from weeks 2 through 12, as the
scaffold degraded and bone formed. The designed topol-
ogy-optimized PPF/-TCP scaffolds degraded with a
stiffness dropping nearly to 60 MPa. The declining stiff-
ness of the scaffold was reinforced by the growing bone
tissue, and the stiffness of the construct remained at a
plateau level between 60 and 70 MPa, which is within
the range of human trabecular bone,50 until apparent bone
resorption occurred at 12 weeks because of the lack of
sufficient mechanical stimulation in the subcutaneous site
(Fig. 4).
In summary, by integrating advantages of topology-
optimized design, biodegradable osteoconductive com-
posite, and ex vivo gene therapy, we can achieve rapid
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osteogenesis and retain the stiffness of constructs to per-
form mechanical functions through the degradation time,
even for ectopic implantations. These results show that
this approach has potential for application in orthotopic
sites with load-bearing demands such as segmental frac-
ture healing and spine arthrodesis.
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